Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Rhea-AI Summary

Cyclo Therapeutics (NASDAQ: CYTH) announced a live webcast presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET. CEO N. Scott Fine and CSO Sharon Hrynkow will present and engage in virtual one-on-one meetings with investors. The presentation will be accessible on the Company’s website and archived for 90 days. Cyclo Therapeutics focuses on developing treatments for diseases, including their orphan drug Trappsol^® Cyclo™ for Niemann-Pick Disease Type C.

- Live webcast presentation on Wednesday, September 22^nd at 10:45 AM ET

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.cyclotherapeutics.com). The webcast replay will be archived for 90 days following the live presentation.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol^® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005076/en/

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Source: Cyclo Therapeutics, Inc.

FAQ

What is the date and time of Cyclo Therapeutics' presentation at the Oppenheimer Summit?

Cyclo Therapeutics will present on September 22, 2021, at 10:45 AM ET.

Who will represent Cyclo Therapeutics during the Oppenheimer Summit?

N. Scott Fine, CEO, and Sharon Hrynkow, PhD, CSO will represent Cyclo Therapeutics.

How can I access the live webcast of Cyclo Therapeutics' presentation?

The live webcast can be accessed on the Cyclo Therapeutics website under the Events section.

What is Trappsol Cyclo and its significance for Cyclo Therapeutics?

Trappsol Cyclo is an orphan drug for Niemann-Pick Disease Type C, currently involved in multiple clinical trials.

Will the webcast of the presentation be available after the live event?

Yes, the webcast will be archived for 90 days following the live presentation.